<DOC>
	<DOCNO>NCT01544998</DOCNO>
	<brief_summary>This study do determine effect subcutaneous ( skin ) injection human B-type natriuretic factor ( BNP ) , Natrecor ( nesiritide ) , hormone produce heart , combination Tadalafil : - The pump function heart - Kidney function - Hormonal function ( level different hormone blood ) person low pump function heart .</brief_summary>
	<brief_title>Tadalafil Nesiritide Therapy Pre-clinical Heart Failure</brief_title>
	<detailed_description>In American Heart Association/American College Cardiology classification heart failure ( HF ) , stage B define patient abnormal heart structure/function ( systolic diastolic dysfunction ) without symptom . This concept preclinical HF base fact abnormal heart structure/function detect complementary method development symptom . Patients abnormality may progress heart failure increase risk adverse cardiac event . Preclinical systolic dysfunction ( PSD ) initial compensated phase leave ventricular systolic dysfunction without symptom HF . We establish diastolic dysfunction common general population present approximately 25 % population age 45 , majority asymptomatic i.e. , preclinical diastolic dysfunction ( PDD ) . Cyclic guanosine monophosphate ( cGMP ) second messenger natriuretic peptide system ( NPS ) nitric oxide system ( NO ) play important role preservation myocardial , vascular , renal function . Hence , disruption signal transduction process may contribute development cardiorenal dysfunction . Type V phosphodiesterase ( PDEV ) metabolize cGMP abundant kidney , vasculature , recently report heart . We others demonstrate renal PDEV up-regulated experimental HF may lead attenuation renal cGMP generation response endogenous exogenous BNP , thus serve mechanism renal resistance BNP . Furthermore , experimental overt HF , 10 day PDEV inhibition treatment result reduction leave ventricular ( LV ) mass , increase LV fractional shortening cardiac output improve renal function . However , chronic PDEV inhibition enhance renal action exogenous BNP , specifically improve glomerular filtration rate ( GFR ) renal cGMP generation . PDEV inhibitor FDA approve erectile dysfunction pulmonary hypertension .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>Group 1 ( PSD ) ejection fraction le 40 % clinical sign symptom congestive heart failure ; minimal distance 6minute walk &gt; 450 meter calculate creatinine clearance equal le 90 ml/min great 30 ml/min , use Modification Diet Renal Disease ( MDRD ) formula assess within past 24 month . If creatinine clearance &gt; 24 month creatinine test drawn screen/enrollment visit . A 6minute walk distance 450 meter Group 2 ( PDD ) ejection fraction great 50 % moderate severe diastolic dysfunction assess Doppler echocardiography , sign symptom congestive heart failure minimal distance 6minute walk &gt; 450 meter calculate creatinine clearance equal le 90 ml/min great 30 ml/min Current anticipate future need nitrate therapy Systolic blood pressure &lt; 90 mmHg &gt; 180 mm Hg Diastolic blood pressure &lt; 40 mmHg &gt; 100 mmHg Resting heart rate ( HR ) &gt; 100 bpm Patients take alpha antagonist cytochrome P450 3A4 inhibitor ( ketoconazole , itraconazole , erythromycin , saquinavir , cimetidine serum protease inhibitor HIV ) . Patients retinitis pigmentosa , previous diagnosis nonischemic optic neuropathy , untreated proliferative retinopathy unexplained visual disturbance Patients sickle cell anemia , multiple myeloma , leukemia penile deformity place risk priapism ( angulation , cavernosal fibrosis Peyronie 's disease ) Contraindication nesiritide . Patients allergy iodine . Valve disease ( &gt; moderate aortic mitral stenosis ; &gt; moderate aortic mitral regurgitation ) Hypertrophic cardiomyopathy Infiltrative inflammatory myocardial disease ( amyloid , sarcoid ) Pericardial disease Have experience myocardial infarction unstable angina , undergone percutaneous transluminal coronary angiography ( PTCA ) coronary artery bypass grafting ( CABG ) within 60 day prior consent , require either PTCA CABG time consent Severe congenital heart disease Sustained ventricular tachycardia ventricular fibrillation within 14 day screen Second third degree heart block without permanent cardiac pacemaker Stroke within 3 month screen evidence significantly compromised central nervous system ( CNS ) perfusion Patients severe liver disease ( AST &gt; 3x normal , alkaline bilirubin &gt; 2x normal ) Serum sodium &lt; 125 milliequivalent ( mEq ) /dL &gt; 150 mEq/dL Serum potassium &lt; 3.2 mEq/dL &gt; 5.7 mEq/dL Prior diagnosis intrinsic renal disease include renal artery stenosis &gt; 50 % Peritoneal hemodialysis within 90 day anticipation dialysis ultrafiltration form require study period Less 21 year age Pregnant nursing woman . Women child bear potential negative pregnancy test study entry use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>